Enoxaparin Market

Enoxaparin Market: Introduction

• Enoxaparin is a low molecular weight heparin (LMWH) derived from heparin. It is used as an anticoagulant to prevent the formation of blood clots and is also known as a 'blood thinner.' Enoxaparin is used to treat various conditions including deep vein thrombosis (DVT), pulmonary embolism in the lungs, acute coronary syndrome, and heart attack.
• Incidence rate of venous thromboembolism in the U.S. was found to be between 0.1% and 0.2%. According to WHO classification, enoxaparin is classified as an essential medicine and is the most commonly prescribed medication in the U.S.
• The enoxaparin market in India is expected to grow at a CAGR of 4.9% from US$ 127.8 Mn in 2016 to US$ 170.2 Mn in 2022. The prevalence of coagulation disorders and government support for pharmaceutical companies are fueling the market.

Global Enoxaparin Market: Key Trends

• The enoxaparin market is expected to grow due to rise in the frequency of chronic and cardiovascular diseases and unmet global demand for blood thinners. Availability of low molecular weight enoxaparin (LMWH) over unfractionated heparin is a major factor expected to propel the market during the forecast period.
• Based on indication, the pulmonary embolism segment dominated the global enoxaparin API market in 2021. This could be ascribed to the high incidence of pulmonary embolism globally. COVID-19 has significantly increased the demand for blood thinners across the world, making it a dominant factor in the global market. In terms of end-user, the pharmaceutical manufacturers segment held the largest share of the global enoxaparin API market in 2021.
• Benefits of low molecular weight heparin over unfractionated heparin are boosting the low molecular weight heparin segment. Low molecular weight heparin is also a better candidate for anticoagulant therapy as it has better bioavailability, predictable dose response, and a longer plasma half-life than unfractionated heparin. Consequently, demand for low molecular weight heparin is expected to increase during the forecast period, boosting the market.
• Government regulatory agencies are imposing regulations on the use of LMWH biosimilars and the approval process. The market is expected to grow as regulatory bodies become more involved in authorizing LMWH biosimilars in these markets. For instance, the European Medicines Agency (EMA) approved the introduction and marketing of Thorinane and Inhixa, biosimilars of low molecular weight heparin (LMWH) enoxaparin in July 2016.
• Increase in the price of enoxaparin API in China has had a significant negative impact on market growth. Adverse effects of enoxaparin during treatment and stringent regulatory standards in developed markets are expected to hamper the enoxaparin market.

North America to Hold Major Share of Enoxaparin Market

• Asia Pacific dominated the global market in 2021. The market is expected to be driven in the next few years by the presence of well-established state-of-the-art facilities. North America and Europe are expected to be attractive markets for enoxaparin due to rise in number of pharmaceutical manufacturers in the region. Latin America is an emerging market and is anticipated to experience moderate growth in the near future. The use of enoxaparin in China is increased in 2019 and is expected to increase further until 2025, propelling the market.
• Europe is expected to be the most lucrative region in the global market during the forecast period. This could be ascribed to the widespread use of low molecular weight heparin in Europe due to its advantages over unfractionated heparin. In Europe, low molecular weight heparins such as enoxaparin, dalteparin, tinzaparin, and certoparin are the most commonly used heparin drugs.

Key Players Operating in Enoxaparin Market

Major players operating in the enoxaparin market are listed below:

• Teva Pharmaceutical Industries Ltd.
• Abbott India Limited
• Pfizer, Inc.
• GlaxoSmithKline Plc.
• Aspen Holdings
• Sanofi S.A.
• Eisai Inc.
• Bristol-Myers Squibb Company
• Boehringer Ingelheim
• Bayer Healthcare AG

Global Enoxaparin Market: Research Scope

Global Enoxaparin Market, by Molecular Weight

• High Molecular Weight
• Low Molecular Weight

Global Enoxaparin Market, by Packaging

• Multi-vails
• Pre-filled Syringes

Global Enoxaparin Market, by Indication

• Deep Vein Thrombosis
• COVID-19
• Acute Coronary Syndrome
• Pulmonary Embolism
• Atrial Fibrillation
• Others

Global Enoxaparin Market, by End-user

• Pharmaceutical Manufacturers
• Contract Manufacturing Organizations
• Research and Development Organization

Global Enoxaparin Market, by Region

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia & New Zealand
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa